item management s discussion and analysis of financial condition and results of operations the following management s discussion and analysis of financial condition and results of operations md a is designed to assist the reader in understanding our consolidated financial statements  the changes in certain key items in those financial statements from year to year and the primary factors that accounted for those changes  as well as how certain accounting principles affect our consolidated financial statements 
the discussion also provides information about the financial results of the various segments of our business to provide a better understanding of how those segments and their results affect our financial condition and results of operations as a whole 
this discussion should be read in conjunction with our consolidated financial statements  including the notes thereto  and the information discussed in part i  item a risk factors 
safe harbor statement under the private securities litigation reform act of this report contains statements not purely historical and which may be considered forward looking statements within the meaning of section a of the securities act  and section e of the securities exchange act of  as amended the exchange act  including statements regarding our expectations  hopes  beliefs  intentions or strategies regarding the future 
these forward looking statements may include statements relating to our business development activities  sales and marketing efforts  the status of material contractual arrangements  including the negotiation or re negotiation of such arrangements  future capital expenditures  the effects of regulation and competition on our business  future operating performance and the results  benefits and risks associated with integration of acquired companies 
investors are cautioned that any such forward looking statements are not guarantees of future performance and involve risks and uncertainties  that actual results may differ materially from those possible results discussed in the forward looking statements as a result of various risks  uncertainties and other factors 
you should not place undue reliance on such forward looking statements as they speak only as of the date they are made  and we assume no obligation to publicly update or revise any forward looking statement even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized 
these factors include  among other things  risks associated with risk based or capitated contracts  increased government regulation related to the health care and insurance industries in general and more specifically  pharmacy benefit management and specialty pharmaceutical distribution organizations  changes in reimbursement rates from government and private payors  the existence of complex laws and regulations relating to our business  increased competition from our competitors  including competitors with greater financial  technical  marketing and other resources 
this report contains information regarding important factors that could cause such differences 
business overview item business overview we provide comprehensive specialty pharmaceutical and pharmacy benefit management pbm services 
our specialty pharmaceutical services specialty services include the comprehensive support  management  dispensing  distribution and data reporting for medications used to treat patients living with chronic health conditions and are provided in various capacities to patients  physicians  payors and pharmaceutical manufacturers 
our pbm services include pharmacy network management  claims processing  benefit design  drug utilization review  formulary management and traditional mail order pharmacy fulfillment 
specialty services and pbm services revenues are derived from our relationships with patients  physicians  pharmaceutical manufacturers and a variety of third party payors  including managed care organizations  as well as third party administrator tpas  self funded employer groups and government programs collectively plan sponsors 
our services are reported under two operating segments i specialty services  and ii pbm and traditional mail services collectively  pbm services 
our specialty services are marketed and sold primarily to patients  physicians  pharmaceutical manufacturers and payors and are focused on chronic health conditions including potentially life threatening or debilitating diseases or genetic disorders which are treated with specialty medications 
these services include the distribution of biotech and other high cost injectable  oral and infusable prescription medications and the provision of therapy management services 
we strive to maximize therapy outcomes through strict adherence to clinical guidelines or protocols for a particular prescription therapy while at the same time managing the costs of such therapies on behalf of a plan sponsor or patient 
our pbm services are offered to plan sponsors and are designed to promote a broad range of cost effective  clinically appropriate pharmacy benefit management services through our network of retail pharmacies and our traditional mail service distribution facility 
over the past several years we have focused on building our specialty services for strategic growth  and have lost a significant amount of pbm services business  including the loss of our contracts with centene corporation and excellerx 
consequently  specialty services revenues represent of our total revenue 
as part of our pbm services  we also administer numerous cash card or discount card programs on behalf of program sponsors or tpas 
these are copay programs that provide savings to customers who present a discount card at one of our participating network pharmacies or who order medications through one of our mail order pharmacies 
under such programs we derive revenue on a per claim basis from the dispensing network pharmacy 

table of contents we plan to grow our infusion business by marketing a broader product offering in our current geographic service area 
this includes adding new therapies to our current focus on immunological blood products  including our most recent focus on patients with hemophilia 
we will work with physicians who utilize our services to support their in office infusion activities and we expect to establish ambulatory infusion centers 
our plan for and beyond is to increase the depth of our business by broadening our model to take advantage of our strength of services and differentiating assets 
we will implement redefined specialty services models to allow for therapy optimization and the management of medications incidental to a physician s service 
critical accounting estimates 
table of contents our consolidated financial statements have been prepared in accordance with u 
s 
generally accepted accounting principles gaap 
in preparing our financial statements  we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities  the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period 
we evaluate our estimates and judgments on an ongoing basis 
we base our estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances  the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources 
our actual results may differ from these estimates  and different assumptions or conditions may yield different estimates 
the following discussion highlights what we believe to be the critical accounting estimates and judgments made in the preparation of our consolidated financial statements 
the following discussion is not intended to be a comprehensive list of all the accounting estimates or judgments made in the preparation of our financial statements  and in many cases the accounting treatment of a particular transaction is specifically dictated by generally accepted accounting principles  with no need for management s judgment in its application 
see our audited consolidated financial statements and notes thereto which appear in 
